CenterBook Partners’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.35M Buy
58,208
+1,868
+3% +$107K 0.16% 146
2026
Q1
$3.42M Buy
+56,340
New +$3.28M 0.18% 147
2024
Q4
Sell
-42,507
Closed -$2.2M 480
2024
Q3
$2.2M Buy
+42,507
New +$1.99M 0.14% 186
2023
Q3
Sell
-7,605
Closed -$486K 423
2023
Q2
$486K Buy
7,605
+782
+11% +$52.4K 0.06% 333
2023
Q1
$473K Buy
+6,823
New +$481K 0.07% 316

Other funds holding BMY

CenterBook Partners's BMY Position: Q2 2026 in Review

CenterBook Partners increased its Bristol-Myers Squibb (BMY) stake by 3.3% in Q2 2026, buying an estimated $107K and bringing the position to 58,208 shares worth $3.35M. The position accounts for 0.16% of the portfolio, ranked #146.

CenterBook Partners first reported a position in BMY in Q1 2023 and has held it in 5 quarters since. The position peaked at $3.42M in Q1 2026. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • CenterBook Partners held 58,208 shares of Bristol-Myers Squibb worth $3.35M as of Q2 2026.
  • CenterBook Partners bought 1,868 Bristol-Myers Squibb shares in Q2 2026, an estimated $107K.
  • Bristol-Myers Squibb made up 0.16% of CenterBook Partners's portfolio in Q2 2026, its #146 holding.
  • CenterBook Partners first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 5 quarters since.
  • CenterBook Partners's Bristol-Myers Squibb position peaked at $3.42M in Q1 2026.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.